Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The epigenetic impact of suberohydroxamic acid and 5-Aza-2'-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression

KS. Trtkova, P. Luzna, DW. Drozdkova, K. Cizkova, L. Janovska, J. Gursky, D. Prukova, I. Frydrych, M. Hajduch, J. Minarik

. 2022 ; 26 (4) : . [pub] 20220831

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024302

Gene inactivation of the cyclin-dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5-Aza-2'-deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53-functionality and IL-6 expression. In both tested myeloma cell lines, a non-methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15INK4b protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53-functional, without IL-6 expression), whereas in the U266 cell line (p53 deleted, expressing IL-6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL-6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5-Aza-2'deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM).

000      
00000naa a2200000 a 4500
001      
bmc22024302
003      
CZ-PrNML
005      
20221031100325.0
007      
ta
008      
221017s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.3892/mmr.2022.12837 $2 doi
035    __
$a (PubMed)36043519
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Trtkova, Katerina Smesny $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
245    14
$a The epigenetic impact of suberohydroxamic acid and 5-Aza-2'-deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL-6 expression / $c KS. Trtkova, P. Luzna, DW. Drozdkova, K. Cizkova, L. Janovska, J. Gursky, D. Prukova, I. Frydrych, M. Hajduch, J. Minarik
520    9_
$a Gene inactivation of the cyclin-dependent kinase inhibitors p16INK4a, p15INK4b and p21WAF is frequently mediated by promoter gene methylation, whereas histone deacetylases (HDACs) control gene expression through their ability to deacetylate proteins. The effect of suberohydroxamic acid (SBHA) and 5-Aza-2'-deoxycytidine (Decitabine) (DAC) treatments on the transcription of CDKN2A, CDKN2B and CDKN1A genes, and their effects on molecular biological behavior were examined in two myeloma cell lines, RPMI8226 and U266, which differ in p53-functionality and IL-6 expression. In both tested myeloma cell lines, a non-methylated state of the CDKN2B gene promoter region was detected with normal gene expression, and the same level of p15INK4b protein was detected by immunocytochemical staining. Furthermore, in myeloma cells treated with SBHA and DAC alone, the expression of both p15INK4b and p21WAF was significantly upregulated in RPMI8226 cells (p53-functional, without IL-6 expression), whereas in the U266 cell line (p53 deleted, expressing IL-6) only p21WAF expression was significantly increased. Moreover, the analysis revealed that treatment with DAC induced DNMT3B enhancement in U266 cells. In conclusion, in myeloma cells with IL-6 expression, significantly increased DNMT3B expression indicated the tumorigenic consequences of 5-Aza-2'deoxycytidine treatment, which requires careful use in diseases involving epigenetic dysregulation, such as multiple myeloma (MM).
650    _2
$a proteiny buněčného cyklu $x genetika $x metabolismus $7 D018797
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a inhibitor p15 cyklin-dependentní kinasy $x genetika $x metabolismus $7 D050762
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x genetika $x metabolismus $7 D019941
650    12
$a DNA-(cytosin-5-)methyltransferasa $x genetika $x metabolismus $7 D004248
650    _2
$a metylace DNA $7 D019175
650    12
$a decitabin $x farmakologie $7 D000077209
650    12
$a epigeneze genetická $7 D044127
650    _2
$a umlčování genů $7 D020868
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-6 $x genetika $x metabolismus $7 D015850
650    12
$a mnohočetný myelom $x genetika $x metabolismus $7 D009101
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
700    1_
$a Luzna, Petra $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
700    1_
$a Drozdkova, Denisa Weiser $u Department of Clinical and Molecular Pathology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
700    1_
$a Cizkova, Katerina $u Department of Histology and Embryology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
700    1_
$a Janovska, Lucie $u Department of Microbiology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
700    1_
$a Gursky, Jan $u Department of Biology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 777 15 Olomouc, Czech Republic
700    1_
$a Prukova, Dana $u Institute of Pathological Physiology, First Faculty of Medicine, Charles University, 121 08 Prague, Czech Republic
700    1_
$a Frydrych, Ivo $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Hajduch, Marian $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, 779 00 Olomouc, Czech Republic
700    1_
$a Minarik, Jiri $u Department of Hemato-Oncology, University Hospital Olomouc, 779 00 Olomouc, Czech Republic
773    0_
$w MED00181650 $t Molecular medicine reports $x 1791-3004 $g Roč. 26, č. 4 (2022)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36043519 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20221031100323 $b ABA008
999    __
$a ok $b bmc $g 1854176 $s 1175592
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 26 $c 4 $e 20220831 $i 1791-3004 $m Molecular medicine reports $n Mol Med Rep $x MED00181650
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace